| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| D/A |
Other
|
|||
| S-4/A | Pre-effective amendment to an S-4 filing |
Registration Statements
|
EX-101.INS - XBRL INSTANCE DOCUMENT | |
| CORRESP | CORRESP |
Other
|
||
| UPLOAD | UPLOAD |
Other
|
||
| D |
Other
|
|||
| S-4 | Registration of securities issued in business combination transactions |
Registration Statements
|
EX-101.INS - XBRL INSTANCE DOCUMENT | |
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| 425 | Filing of certain prospectuses and communications in connection with business combination transactions |
Other
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
